{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:47:58Z","timestamp":1790362078678,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaad.2020.07.044","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:56:10Z","timestamp":1594950970000},"page":"1554-1561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study"],"prefix":"10.1016","volume":"84","author":[{"given":"Christina L.","family":"Boull","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gardeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Abdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolee","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie M.","family":"Carlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnelly","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheilagh M.","family":"Maguiness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Moertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina L.","family":"Vivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Coughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lara-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.07.044_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2020.07.044_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.07.044_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9992","key":"10.1016\/j.jaad.2020.07.044_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2020.07.044_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2020.07.044_bib6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/fon.12.43","article-title":"BRIM-1,-2 and-3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600E mutation","volume":"8","author":"Young","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.jaad.2020.07.044_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdv072","article-title":"A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)","volume":"26","author":"Blumenschein","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2020.07.044_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","article-title":"Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma","volume":"71","author":"Sanlorenzo","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.07.044_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.07.044_bib16","doi-asserted-by":"crossref","first-page":"217.e1","DOI":"10.1016\/j.jaad.2014.04.013","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.07.044_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ijd.12205","article-title":"Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions","volume":"53","author":"Curry","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.07.044_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"26","key":"10.1016\/j.jaad.2020.07.044_bib19","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2020.07.044_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4_suppl","key":"10.1016\/j.jaad.2020.07.044_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.409","article-title":"A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270)","volume":"36","author":"Aung","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2020.07.044_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN)","volume":"36","author":"Geoerger","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2020.07.044_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pde.13038","article-title":"Cutaneous reactions in children treated with trametinib for neural tumors","volume":"34","author":"Boull","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib26","doi-asserted-by":"crossref","first-page":"e27682","DOI":"10.1002\/pbc.27682","article-title":"Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study","volume":"66","author":"Song","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib27","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1111\/pde.13613","article-title":"Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis","volume":"35","author":"Chen","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.07.044_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/pde.13381","article-title":"Comment on \u201cBumps in\u00a0the\u00a0road: panniculitis in children and adolescents treated\u00a0with vemurafenib\u201d","volume":"35","author":"Bhat","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2020.07.044_bib29","series-title":"Criteria for Adverse Events v4.0","year":"2009"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"7287","key":"10.1016\/j.jaad.2020.07.044_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jaad.2020.07.044_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"issue":"7287","key":"10.1016\/j.jaad.2020.07.044_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jaad.2020.07.044_bib35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2015.01.018","article-title":"Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy","volume":"72","author":"Anforth","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.07.044_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2015.12.003","article-title":"BRAF inhibitor therapy\u2013associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression","volume":"50","author":"Mudaliar","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jaad.2020.07.044_bib37","first-page":"386","article-title":"Keratosis pilaris: a clinico-histopathologic study","volume":"70","author":"Sallakachart","year":"1987","journal-title":"Med Assoc Thai"},{"issue":"6","key":"10.1016\/j.jaad.2020.07.044_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2133.1994.tb03406.x","article-title":"Natural history of keratosis pilaris","volume":"130","author":"Poskitt","year":"1994","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.07.044_bib39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jid.2016.12.012","article-title":"Do the side effects of BRAF inhibitors mimic RASopathies?","volume":"137","author":"Sfecci","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4,\u00a0suppl. 1","key":"10.1016\/j.jaad.2020.07.044_bib40","article-title":"MEK inhibitor-induced chronic paronychia: 8204","volume":"81","author":"Zhou","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220322131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220322131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:47Z","timestamp":1759273127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220322131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0190962220322131"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.07.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}